Product Wiki · Recalls · EU Safety Gate (RAPEX)

Tablier Prisunic 2 — recall A12/00941/24

EU Safety Gate (RAPEX) · France · 2024-04-19 · Serious risk

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked on this page. No AI-generated text appears on this page. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/00941/24
Date of alert
2024-04-19
Country / jurisdiction
France
Risk level
Serious risk
Risk type
Chemical
Brand
Monoprix
Product category
Clothing, textiles and fashion items
Product type
Apron
Barcode (EAN/GTIN)
3614913485754
Reported risk: The product has an excessive concentration of cadmium (measured value up to 0.08% by weight). Cadmium is harmful to human health because it accumulates in the body, can damage the kidneys and bones and it may cause cancer. Moreover, the plastic material of the product contains an excessive amount of bis(2-ethylhexyl) phthalate (DEHP), (measured value up to 22.8% by weight). This phthalate may harm the health by causing possible damage to the reproductive system.
What to do

Check whether your product matches this notice (name, batch, dates). If it does, stop using it and follow the instructions in the official notice — refund, return, repair or disposal are set by the issuing authority and the business, and they differ per recall. Official notice from EU Safety Gate (RAPEX) →

Action taken by the authority
Type of economic operator taking notified measure
Distributor
Category of measure
Withdrawal of the product from the market
Date of entry into force
01/02/2024
Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10012694

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.